About Sotagliflozin Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose ...
Lexicon Pharmaceuticals (($LXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Lexicon Pharmaceuticals’ recent ...
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to ...
Lexicon Pharmaceuticals, Inc. announced a conference call and webcast scheduled for March 3, 2025, at 8:00 a.m. ET to discuss topline results from the Phase 2b PROGRESS study of pilavapadin (LX9211), ...
Discovered using Lexicon’s unique approach to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback